Comparing The Effect of Finasteride With Dutasteride on Hair Growth in Male Androgenetic Alopecia

Phase 3

Recruiting

Conditions: Androgenetic alopecia.
Androgenic alopecia, unspecified
L64.9

Registration Number: IRCT20231025059850N1

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Male

Target Recruitment: 80

Inclusion Criteria

Male patients diagnosed with moderate to severe androgenetic alopecia (grade 3, 4, 5 Hamilton-norwood scale)
Do not have any of the followings (Non-inclusion criteria): any serious systemic disease, psoriasis or lichen planus; other types of alopecia (including anagen effluvium, telogen effluvium and scarring alopecia); any andrological condition known to affect semen parameters and male fertility (including varicocele, cryptorchidism, testicular cancer, testicular trauma, orchitis, urinary tract infection; previous chemotherapy or radiotherapy); history of hair transplant; history of breast cancer or male infertility in first degree relatives.
Patients who have not received any treatment for alopecia in the past three months

Exclusion Criteria

Serum levels of prostate specific antigen (PSA) greater than 2 ng/ml
Abnormal liver function tests (except chronic stable hepatitis B and C)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of hair follicles. Timepoint: Obtaining standard photographic pictures before the intervention and 25 weeks after the intervention. Method of measurement: A 7-point questionnaire developed by a physician based on the comparison of standard photographic pictures (checking the thickness and number of hairs).;Hair growth rate. Timepoint: perform scalp dermoscopy before the intervention and 25 weeks after the intervention. Method of measurement: A 7-point questionnaire developed by a physician based on the comparison of phototrichograms (checking the thickness and number of hairs).;Patient satisfaction score. Timepoint: before the intervention and 25 weeks after the intervention which is the end of the study. Method of measurement: ????? ?????? ????.

Secondary Outcome Measures

Name	Time	Method
Sexual dysfunction. Timepoint: Before the intervention and 25 weeks after the intervention which is the end of the study. Method of measurement: Interview with the patient.;Erectile dysfunction. Timepoint: Before the intervention and 25 weeks after the intervention which is the end of the study. Method of measurement: Interview with the patient.;Any side effects following consumption of finasteride and dutasteride. Timepoint: Every 3 months. Method of measurement: Interview with the patient.